CURRICULUM VITAE
Yan Xu, M.D., Ph.D., FCP

225 Binney Street, Cambridge, MA 02142
+001 908-462-2057 (cell) ● yan.xu1@biogen.com

PROFESSIONAL OVERVIEW

Experience in clinical pharmacology & pharmacometrics, clinical research and medical practice. Special interests in population PK and PK/PD, biologic drug development and model-informed drug development (MIDD).

Core Qualifications

- Drug Development (Phase 1-4)
- Clinical Research
- Translational Medicine
- Global Regulatory NDA/BLA Submissions
- Dose Optimization
- Pediatric Extrapolation
- Population PK, PK/PD, Trial simulation, MBMA & PBPK
- Therapeutic Areas of oncology, immunology, neuroscience, rare disease and infectious disease
- Biologics (mAb, BsAb), Small molecules, ASO/siRNA, Cell therapy
- NONMEM, R, Phoenix-Winonlin & simCYP
- Scientific community leadership

Major Achievements

- Over 17-year industry experience in clinical pharmacology & pharmacometrics and 5-year medical practice (medical intern and resident).
- Develop and execute clinical pharmacology strategy and innovative M&S analysis to enable key development milestones e.g., NME, FIH, POC, Phase 3, global registration and licensing.
- Serve in governance committees to communicate clinical pharmacology strategy and influence clinical development plan and business decisions.
- Supported numerous compounds to meet critical drug development milestones, including the global approval of Tecvayli® (multiple myeloma [MM]), Carvykti ® (MM), Darzalex Faspro® (DPd Combination, MM), Stelara® (Crohn's disease, Ulcerative Colitis), Tremfya® (Psoriasis), Isentress® (HIV, Pediatrics), and China approvals of Simnotrelvir (COVID) and Cosela® (chemotherapy-induced myelosuppression).
- Member of ACCP since 2016 (FCP since 2019); Serve in ACCP education committee since 2018; Co-Chair Symposiums in multiple ACCP Annual Conferences; ACCP Mentor and Working groups lead.
- Serve in editorial board of JCP, JPS and CTS; peer-reviewers for other key pharmaceutical/biomedical journals including CPT, PSP, JPET etc.
- Over 35 full manuscripts/reviews published in prestigious pharmaceutical/biomedical journals; 5 book chapters; 15+ invited internal/external oral presentations and 50+ poster/podium presentations in international/national conferences.

EDUCATION

Master, Pharmacometrics — **2015**
University of Maryland, School of Pharmacy & Medicine — Baltimore, MD

Ph.D., Pharmaceutical Science — **2006**
Ernest Mario School of Pharmacy, Rutgers, the State University of NJ — Piscataway, NJ

Master, Clinical Medicine — **2000**
School of Medicine, Peking University — Beijing, China

B.S., Clinical Medicine (Equivalent to MD) — **1998**
School of Medicine, Peking University — Beijing, China

PROFESSIONAL EXPERIENCE

Senior Director & Section Head **2023- Present**
Clinical Pharmacology and Pharmacometrics (CPP) Cambridge, MA
Biogen

Vice President & Global Head **2022- 2023**
Clinical Pharmacology and Translational Science Cambridge, MA
Simcere Pharmaceuticals

Senior Director/Director/Associate Director & Group Lead **2015- 2022**
Clinical Pharmacology & Pharmacometrics (CPP) Spring House, PA
Johnson & Johnson

Associate Principal Scientist/ Senior Scientist **2007-2015**
Quantitative pharmacology and pharmacometrics (QP2) West Point, PA
Merck Research Laboratory

Research Investigator **2006-2007**
Metabolism and Pharmacokinetics (MAP) Wallingford, CT
Bristol Myers Squibb Co.

Summer Intern **Summer, 2004**
PPDM (PK, PD and Drug Metabolism) West Point, PA
Merck Research Laboratory

Teaching Assistant **2002-2006**
Ernest Mario School of Pharmacy West Point, PA
Rutgers, the State University of NJ

Medical Resident **1998-2001**
Obstetrics & Gynecology Beijing, China
People's Hospital of Peking University & Beijing Friendship Hospital

Medical Intern **1996-1998**
Peking University First Hospital Beijing, China

SLECTED CONTINUING EDUCATION

Leadership
Executive Presence, Executive Analytical Leadership, Executive Presentation, Business Foundations, Successful Negotiator, Influence without Authority, Strategic Communication, Project Management, High Impact Business Writing, etc.

Technical
Machine Learning (Post-graduate certificate; Standford ONLINE), Translational PK/PD, Monolix, Advanced NONMEM, Comparator Modeling (MBMA), Pediatric Modeling, simCYP, R for pharmacometrics, Clinical Trial Simulation, Optimal Design and PK/PD, Dose-finding workshop, Exposure-response workshop, Biologics PK/PD, etc.

ACTIVITIES

Current Professional Affiliations

- Fellow, American Colleges of Clinical Pharmacology (ACCP)
  - Member: Education Committee of ACCP
- Member, International Society of Pharmacometrics (ISOP)
  - Chair Elect: Award Committee of ISOP
- Member, American Society of Clinical Pharmacology and Therapeutics (ASCPT)
  - Member: Annual Meeting Proposal Review Committee of ASCPT
- Member, American Association of Pharmaceutical Science (AAPS)

Editorial Activities

EDITORIAL BORAD

- Journal of Clinical Pharmacology
- Journal of Pharmaceutical Science
- CPT: Clinical and Translational Science

REVIEWER

- Clinical Pharmacology and Therapeutics
- CPT: Pharmacometrics & Systems Pharmacology
- Journal of Pharmacology and Experimental Medicine
- Molecular Pharmaceutics
- Current Pharmacology Reports
- British Medical Journal

FELLOWSHIP & AWARD

2022-2023	Leadership Award from Simcere
2019-2022	Inspire Award from Janssen - multiple
2019	Top Abstract Award from ASCPT
2019	Outstanding Contribution in Reviewing from J. Pharm. Sci.
2018	R&D Spark Innovation Award from Janssen
2017-2021	Leadership Award from Janssen - multiple
2017	Inclusion Award from Janssen
2015-2018	Encore Awards from Janssen - multiple
2012	Corporate Merck Sigma - Yellow Belt
2011-2014	Award for Excellence from Merck - multiple
2010	STAR Award from Merck
2009	Special Achievement Award from Merck
2006	Graduate Student Travel Awards from Society of Toxicology
2003-2005	Graduate Conference Travel Award from Graduate School of Rutgers
1998	Fellowship from International Health Center, Ministry of Health of China
1993-2000	Scholarship from Peking University

ORIGINAL RESEARCH PUBLICATIONS

Miao X, Wu LS, Lin SXW, **Xu Y,** Chen Y, Iwaki Y, et al. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. *Target Oncol.* 18(5):667-684 **(2023)**

Yang XM, Yang Y, Yao BF, **Xu Y**, etc. A First-in-human Phase 1 Study of Simnotrelvir, a 3CL-Like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects. *Eur J Pharm Sci.* Dec 1;191:106598 **(2023)**

Sharma G, Chen Y, **Xu Y.** Neonatal Fc Receptor (FcRn) Targeting Therapeutic Proteins – A Focused Review of Pharmacokinetics and Pharmacodynamics. *Curr Pharmacol Rep. [Review]* 9, 341–352 **(2023)**

Kimball AB, Podda M, Alavi A, Miller M, Shen YK, Li S, **Yan X**, etc. Guselkumab for the Treatment of Patients with Moderate-to-severe Hidradenitis Suppurativa: A Phase 2 Randomized Study. *J Eur Acad Dermatol Venereol.* 37(10):2098-2108 **(2023)**

Zhou J, **Xu Y,** Chen Y, Su Y, Xu Z, Zhou H. Model-based Investigation of Sub-optimal Clinical Efficacy of Tesnatilimab, an Anti- Natural Killer Group 2 Member D (NKG2D) Monoclonal Antibody, in Moderately to Severely Active Crohn's Disease. *J Clin Pharmacol.* 63(8):928-942 **(2023)**

Xu Z, Leu JH, **Xu Y**, Nnane I, Liva S, Wang-Lin SX, Kudgus-Lokken R, Vermeulen A, Ouellet D**.** Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of the Intravenous Dose Regimen: A Systematic Review. *Clin Pharmacol Ther. [Review]* **(2022)** Dec 14. [Epub ahead of print].

Dosne A, Li X, Luo M, Nnane I, Kampfenkel T, Carson R, Amin H, Zhou H, Sun T, **Xu Y.** Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *Br. J Clin Pharmacol.* **(2022)** Dec 9. [Epub ahead of print].

Shao J, Xu Z, **Xu Y**. Integrated Population Pharmacokinetic Analysis of Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects Eur J Drug Metab Pharmacokinet 47(4):537-548 **(2022)**

Xu Y, Langeivn B, Zhou H, Xu Z. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies – Is Allometry a Reasonable Choice? *J Clin Pharmacol. Dec;*60(12):1573-1584 **(2021)**

Zhu Y, **Xu Y**, Zhuang Y, Piantone A, Shu C, Chen D, Zhou H, Xu Z, Sharma A. Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients with Moderate-To-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. *Clin Transl Sci* 13(6):1217-1226 **(2020)**

Xu Y, Hu C, Chen Y, Xin M, Adedokun OJ, Xu Z, Sharma A, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults with Moderately to Severely Active Ulcerative Colitis. *J Clin Pharmacol.* 60(7): 889–902 **(2020)**

Xu Y, Miao X, Ravenstijn P, Hijzen A, Schmidt M, Nandy P, Zhou H. Translational Model-Informed Dose Selection for a Positron Emission Tomography (PET) Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist. *Clin Transl Sci.* 13(2):309-317 **(2020)**

Xu Y, Sharma A, Chen Y, Zhou H. What We Can Learn from Current Inflammatory Bowel

Disease (IBD) Biological Therapy—Dose Regimen and Others. *Curr Pharmacol Rep.* 5(3):115-130 *[Review]* **(2019)**

Xu Y, Adedokun OJ, Chan D, Hu C, Xu Z, Strauss R, Hyams JS, Turner D, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children with Moderately to Severely Active Ulcerative Colitis. *J Clin Pharmacol.* 59(4):590-604 (**2019**)

Du L, Wenning L, Migoya E, **Xu Y**, Carvalho B, Brookfield C, Witjes H, Greef R, Lumbiganon P, Sangkomkamhang U, Titapant V, Duley L, Long Q, Oladapo OT. Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Pregnant Women with Preeclampsia. *J Clin Pharmacol.* 59(3):374-385 (**2019**)

Hu C, **Xu Y**, Zhuang Y, Hsu B, Xu Z, Sharma A, Zhang L, Zhou H. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab. *J Pharmacokinet Pharmacodyn*. 45(5):679-691 (**2018)**

Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Sharma A, Zhou H. Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients with Moderately to Severely Active Rheumatoid Arthritis. *J Clin Pharmacol.* 58(11):1501-1515 **(2018)**

Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Zhou H. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients with Moderately to Severely Active Rheumatoid Arthritis. *J Clin Pharmacol.* 58(7):939-951 **(2018)**

Hoseyni H, **Xu Y** (co-1st author), Zhou H. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? *J Clin Pharmacol.* 58(7):864-876 *[Review]* **(2018)**

Chen Y, **Xu Y.** Pharmacokinetics of Bispecific Antibody. Current Pharmacology Reports. 3: 126 *[Review]* **(2017)**

Xu Y, Li YF, Zhang D, Rizk M, Gobburu J, Comisar W. Characterizing Class Specific Exposure- Viral Load Suppression Response of HIV Antiretrovirals Using a Model Based Meta-Analysis. *Clin Transl Sci.* 9(4):192-200 (**2016**)

Xu Y, Ou M, Keough E, Roberts J, Koeplinger KA, Lyman M, Fauty S, Carlini E, Stern M, Zhang R, Yeh S, Mahan E, Wang Y, Slaughter D, Gindy ME, Raab CE, Thompson C, Hochman J. Quantitation of Physiological & Biochemical Barriers to siRNA Liver Delivery via Lipid NanoParticle (LNP) Platform. *Mol Pharmaceutics*. 11(5):1424-34 **(2014)**

Zhang Y, Arrington L, Boardman D, Davis J, **Xu Y,** Difelice K, Stirdivant S, Wang W, Budzik B, Bawiec J, Deng J, Beutner G, Seifried D, Stanton M, Gindy M, Leone A. The development of an in vitro assay to screen lipid-based nanoparticles for siRNA delivery. *J Control Release.* 174C:7-14 **(2013)**

Pei Y, Hancock PJ, Zhang H, Bartz R, Cherrin C, Innocent N, Pomerantz CJ, Seitzer J, Koser

ML, Abrams MT, **Xu Y**, Kuklin NA, Burke PA, Sachs AB, Sepp-Lorenzino L, Barnett SF. Quantitative evaluation of siRNA delivery in vivo. *RNA*. 16(12):2553-63 **(2010)**

Xu Y, Agrawal S, Cook TJ, Knipp GT. Maternal Di-(2-ethylhexyl)-phthalate Exposure Influences Essential Fatty Acid Homeostasis in Rat Placenta. *Placenta,* 29(11):962-9 (**2008**)

Xu Y, Wang Q., Cook TJ, Knipp GT. Effects of placental fatty acid metabolism and regulation by peroxisome proliferator activated receptor on pregnancy and fetal outcome. *J. Pharm. Sci.* 96(10):2582-606 *[Review]* **(2007)**

Xu Y, Agrawal S, Cook TJ, Knipp GT. Di-(2-ethylhexyl)-phthalate affects fetal brain lipid profiling in rat upon maternal exposure. *Arch Toxicol.* 81(1):57-62 **(2007)**

Xu Y, Knipp GT, Cook TJ. Effects of di-(2-ethylhexyl)-phthalate and its metabolites on the lipid profiling in rat HRP-1 trophoblastic cells. *Arch. Toxicol.* 80(5):293-8 **(2006)**

Xu Y, Knipp GT, Cook TJ. Expression of COX isoforms in developing rat placenta and trophoblast cell models. *Mol. Pharm.* 2(6):481-90 **(2005)**

Xu Y, Cook TJ, Knipp GT. Effect of di-(2-ethylhexyl)-phthalate and its metabolites on fatty acid homeostasis regulating proteins in HRP-1 cells. *Toxicol. Sci.* 84(2):287-300 **(2005**)

Xu Y, Knipp GT, Cook TJ. Expression of CYP4A isoforms in developing rat placenta and trophoblast cell models. *Placenta*, 26(2-3):218-25 **(2005)**

Wang SM, **Xu Y** and Yu YZ. Activity and localization of inducible nitric oxide synthase in lower segment of myometrium and placenta at late pregnancy and delivery. *Chinese J. Prac. Obs.& Gyn.* 18(11):670-673 **(2002)**

Xu Y, Wang SM. Progress in research of labor onset. *Beijing Med. J*. 3:171-174 *[Review]* **(2001)**

Xu Y, Wang SM. Relationship between nitric oxide and labor onset. *Chin. J. Obs. & Gyn*. 36(3):179-181 **(2001)**

Xu Y, Wang SM. Myoma and pregnancy. *Chinese J. Clin. Obs.& Gyn*. 1(4):244-245 *[Review]* **(2000)**

CONTRIBUTION IN BOOK CHAPTERS

Geist BJ, Zheng S, **Xu Y.** Therapeutic Antibody Development. In *Remington: The Science and Practice of Pharmacy*. 23rd ed. Editor: Adejare A, Academic Press, pp 437-462 **(2020)**.

Xu Y, Kimko H. Pharmacometrics, A Quantitative Decision-Making Tool in Drug Development. In *Quantitative Methods in Pharmaceutical Research and Development*. Editors: Marchenko OV & Katenka NV, Springer, Cham, pp 175-261 **(2020)**.

Zhou H, **Xu Y,** Sharma A. Antibody-Based Biotherapeutics in Inflammatory Diseases. In *Pharmaceutical Biotechnology.* Editors: Crommelin DJA, Sindelar RA, Meibohm B, Springer Press. 5th ed. Springer Press. New York, NY, pp 557-618 **(2019)**

Bhardwaj RK, Herrera-Ruiz DR., **Xu Y,** Carl SM, Cook TJ, Knipp GT. Intestinal Transporters in Drug Absorption. In *Biopharmaceutics Applications in Drug Development.* Editors: Krishna R and Yu L. Kluwer Press, New York, NY, pp 175-261 **(2007)**.

Xu Y, Cook TJ, Knipp GT. Methods for Investigating Placental Fatty Acid Transport and Metabolism, in *Methods in Molecular Medicine* Series, *Placental and Trophoblast Methods and Protocols Vol. II*, Editors: Soares MJ and Hunt JS. Humana Press, Totowa, NJ, Volume 122: pp 265-284 **(2006)**.

SELECTED INVITED PRESENTATIONS

Xu. Y. Model Informed Drug Development (MIDD) – Past, Present and Future. University of Minesoda Experimental and Clinical Pharmacology. Feb 14th **(2024)**

Xu. Y, Jones A, Gopalakrishnan M. Alumni Panel Session at UMB MS-Pharmacometrics Virtual Graduation Ceremony. May 2nd **(2023)**

Xu. Y. MIDD in Drug Development - An Industry's Perspective. Drug Information Association (DIA) China. Webinar June 8th **(2022)**.

Xu Y (*Symposium Chair*), Schmidt S, Smith P, Wang Y. What's Next in Model-Informed Drug Development?-Joined Pharmacometrics and Epidemiological (RWD) Approach. Amerian College of Clinical Pharmacology Annual Conference (Virtual). September 15th **(2020)**

Xu Y (*Symposium Chair*)**,** Gobburu J, Kimko H, Paul S, Wang Y**.** What to Do After a Pivotal Trial Has Failed Primary Endpoint Assessment - Totality of Evidence-based Drug Development Challenges & Opportunities. ACCP, San Diego, CA. Oct 9th **(2017)**

Xu Y, Hartmann G, Gibson C. Modeling & Simulation For Informed Decision Making in Pediatric Drug Development with simCYP. simCYP Webniar**.** Jan. 21st **(2014)**

10+ other invited presentations in internal/external conferences.

SELECTED ABSTRACTS

Xu Y, Schmitz N, Jackson B, Barbey C. Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus. ACCP Annual Conference **(2024)** *Submitted.*

Schmitz N, Mai Abdelmageed M, **Xu Y**. Trends in First-in-Human Trials of Intrathecal Antisense Oligonucleotide Therapies: Insights into Dose Selection, Dose Escalation, and Early Clinical Development. ACCP Annual Conference **(2024)** *Submitted.*

Xu Y, Huang X, Gao F, Tang R. Assessment of Anti-Drug Antibody (ADA) Incidence in Subcutaneously Administrated Antibody-based Therapeutics Approved Between 2012-2022. Amerian College of Clinical Pharmacology Annual Conference. Seattle WA In *Clin Pharmacol Drug Dev*. 12(S1) [Abstract 118] **(2023)**

Pérez-Ruixo JJ, Zhu Y, Neyens M, Jouvin MH, Ramchandren S, **Xu Y,** Leu JH, Dosne AG, Xiong Y, Valenzuela B, Ling L, Nandy P, Sun H. Nipocalimab Dose Selection for A Phase 3

Study in Adult Patients with Generalized Myasthenia Gravis. MDA Clinical & Scientific Conference, Dallas, Texas **(2023)**

Tang BH, Zhang R, Chong R, Yao BF, Hao GX, Zhang W, **Xu Y**, Zhao W. Model-informed human Pharmacologically Active Dose Prediction for SIM0235, an anti-Tumor Necrosis Factor Receptor-2 Monoclonal Antibody. Amerian College of Clinical Pharmacology Annual Conference. N Bethesda, MD In *Clin Pharmacol Drug Dev*. 11(S1):11 [Abstract 061] **(2022)**

Bei D, Shao J, **Xu Y,** Vermeulen A. Pharmacokinetic Drug Interaction Between Nipocalimab and Fremanezumab in Healthy Subjects. American Association of Neuromuscular & Electrodiagnostic Medicine Annual Conference. Nashville, Tennessee [Abstract 129] **(2022)**

Xu Y, Chen Y, Leu L, Zhuang Y, Sheng S, Liu Y, Agarwal P, Zhou H, Xu Z**.** Influence of Rheumatoid Factor and Anti-citrullinated Protein Antibodies on the Pharmacokinetics of IgG-based Therapeutic Proteins. Amerian College of Clinical Pharmacology Annual Conference (Virual). In *Clin Pharmacol Drug Dev*. 9(S2):11 [Abstract 016] **(2020)**

Shao J, Hartingsveldt B, Zhou H, Xu Z, **Xu Y.** Meta-analysis of Dose Escalations for Monoclonal Antibodies in First-in-Human Trials. Amerian College of Clinical Pharmacology Annual Conference (Virual). In *Clin Pharmacol Drug Dev*. 9(S2):17 [Abstract 024] **(2020)**

Xu Y, Kosoglou T, Strauss RS, Zhou H. Application of Translational Modeling to Inform Clinical Development of JNJ 67864238 (PTG-200), An Orally Administrated Locally-Acting Peptide Antagonist of IL-23 Receptor for the Treatment of Inflammatory Bowel Disease (IBD). Amerian College of Clinical Pharmacology Annual Conference, Chicago, IL. In *Clin Pharmacol Drug Dev*. 8(S1):53 [Abstract 072] **(2019)**

Sharma A, **Xu Y**, Chen Y, Zhou H. Placebo Remission Rates in Crohn's Disease Induction Treatment: Time Course and Potential Influencing Factors. ASCPT, Washington, DC. in *Clin Pharmacol Ther.* 105 (S1): S101 [Abstract PIII-103] (**2019**)

Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Sharma A, Zhou H. Longitudinal Exposure-Response Analysis of CDAI Score in Rheumatoid Arthritis Patients Treated with Sirukumab. ACOP, San Diego, CA in *J Pharmacokinet Pharmacodyn* 45:S121 (Abstract W-070) **(2018)**

Xu Y, Zhuang Y, Hu C, Hsu B, Xu Z, Sharma A, Zhou H. Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis. ACR/ARHP, Chiago, IL in *Arthritis Rheumatol.* 70 (S10). [Abstract] **(2018)**

Xu Y, Adedokun OJ, Chan D, Hu C, Xu Z, Strauss R, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Pediatric Patients with Moderate to Severe Ulcerative Colitis. Amerian College of Clinical Pharmacology Annual Conference, Bethesda, MD. In *Clin Pharmacol Drug Dev.* 5(S1) Abstract 072 **(2016)**

Xu Y, Hartmann G, Gibson C. etc. Utility of Physiologically based Pharmacokinetics in Pediatric Drug Development. ACOP5, Las Vegas, NV. in *J Pharmacokinet Pharmacodyn.* 41 (S1) Abstract M046. **(2014)**

Hartmann G, Gibson G, Rizk M and **Xu Y**. Retrospective Analysis of Raltegravir (Isentress™)

Oral Pharmacokinetics in Healthy Volunteers Using the SimCYP PBPK Model. SimCYP Consortium. Sheffield , UK. **(2012)**

Xu Y, Ou M., Roberts J, Keough E., Koeplinger K, Lyman M, Fauty S, Carlini E, Stern S, Yeh S, Mahan L, Zhang R, Wang Y, Abrams M, Gindy M and Hochman J. Evaluating siRNA liver delivery efficiency via lipid nanoparticle (LNP) platform. DIA/FDA Oligonucleotide based Therapeutics, Washington, DC (**2012**)

Xu Y, Koeplinger K, Stroh M, Aslamkhan A, Meacham DA, Carlini E, Shi B, Matter A, Tao W, Pei Y, Hancock P, Marc A, Koser M, Lyman M, Murphy M, Stanton M, Raab R, Hochman J. Small interfering RNA (siRNA) delivery efficiency evaluation and PK/PD relationship exploration. Annual AAPS National Conference and Exposition, Washington D.C., *in AAPS Journal,* 13(S2) Abstract R6393 **(2011)**

40+ other poster and podium presentations in international/national conferences.

END